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Abstract
Background: Cobalt chromium coronary stents are increasingly being used in percutaneous
coronary interventions. There are, however, no reliable data about the characteristics of unfolding
and visibility of this stent alloy in vivo. The aim of this study is to compare cobalt chromium coronary
stents with conventional stainless steel stents using intracoronary ultrasound.
Methods: Twenty de novo native coronary stenoses ≤ 20 mm in length (target vessel reference
diameter ≥ 2.5 and ≤ 4.0 mm) received under sequential intracoronary ultrasound either a cobalt
chromium stent (Multi-Link Vision®; n = 10) or a stainless steel stent (Multi-Link Zeta®; n = 10).
Results: For optimal unfolding, the cobalt chromium stent requires a higher balloon deployment
pressure (13.90 ± 2.03 atm) than the stainless steel stent (11.50 ± 2.12 atm). Furthermore, the
achieved target vessel diameter of the cobalt chromium stent (Visibility-Index QCA/IVUS Multi-
Link Vision®1.13 / Multi-Link Zeta® 1.04) is more easily overrated by Quantitative Coronary
Analysis.
Conclusion:  These data indicate that stent material-specific recommendations for optimal
implantation pressure and different stent material with an equal design should both be considered
in interpreting QCA-analysis.
Background
With the addition of coronary stents to percutaneous cor-
onary intervention (PCI), the incidence of re-stenosis has
been significantly reduced. Unfortunately, re-stenosis
rates still range from 16% to 32 %[1]. Efforts to reduce re-
stenosis include coating of conventional stents and use of
alternative materials and design. Drug Eluting Stents
(DES) are already established in clinical practice[2],
whereas little data are available with respect to innovative
stent material.
Cobalt chromium represents a more biocompatible mate-
rial that is being increasingly used in coronary stents
(Guidant Multi-Link Vision®/Guidant Corporation,
Driver-Stent®/Medtronic, Costar-Stent®/Biotronic). In
comparison with stainless steel, cobalt chromium has a
higher radial strength and radiopacity for similar electron-
egativity. This allows for the production of thinner struts
with a similar radiological visibility[3].
Although, results of two cobalt chromium registries[3,4]
are already published, there are no data describing the
Published: 28 October 2005
Current Controlled Trials in Cardiovascular Medicine 2005, 6:17 doi:10.1186/1468-6708-6-17
Received: 18 August 2005
Accepted: 28 October 2005
This article is available from: http://cvm.controlled-trials.com/content/6/1/17
© 2005 Hagemeister et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Current Controlled Trials in Cardiovascular Medicine 2005, 6:17 http://cvm.controlled-trials.com/content/6/1/17
Page 2 of 4
(page number not for citation purposes)
basic characteristics of unfolding of a cobalt chromium
stent. This information would be important to know in
developing clinical recommendations for different alloys,
since optimal inflation and complete adherence to vessel
wall are key factors affecting the incidence of re-stenosis.
We investigated the balloon deployment pressure-related
behaviour of a cobalt chromium stent (Multi-Link
Vision®), comparing it to a similarly designed conven-
tional stainless steel stent (Multi-Link Zeta®) using intra-
vascular ultrasound. We also evaluated radiological
visibility of both stents and the influence of radiological
visibility on QCA-analysis.
Methods
Eighteen consecutive patients (14 men, 4 women, mean
age 61 ± 9 years) with twenty single, de novo native coro-
nary stenoses ≤ 20 mm in length were blindly randomised
to either a Multi-Link Vision® cobalt chromium stent (n =
10) or to a Multi-Link Zeta® stainless steel stent (n = 10).
Additional criteria for inclusion were age ≥ 18 years, clin-
ical angina and/or a positive functional study and a target
vessel reference diameter ≥ 2.5 mm and ≤ 4 mm.
Patients were excluded from the study if they presented
with cardiogenic shock, acute coronary syndrome, intrac-
oronary thrombus, vessel occlusion, target lesions in the
left main artery, ostial or bifurcational stenosis, calcifica-
tion of ≥ 180° of vessel circumference by intravascular
ultrasound (IVUS), diabetes and/or known hypersensitiv-
ity to aspirin and clopidogrel. The study was approved by
the ethics committee of the University of Cologne and all
patients signed written informed consent before
participating.
Percutaneous coronary intervention was performed in
accordance with standard clinical procedures, and stent
implantation without predilatation ("primary stenting")
was encouraged. Pretreatment included an oral clopidog-
rel loading dose of 300 mg and aspirin 500 mg the day
before intervention. Peri-interventional, weight-adapted
heparin was given intravenously with consecutive control
of activated clotting time. Implantation was performed
with a primary balloon deployment pressure of 10 atmos-
pheres (atm). If IVUS target criteria were not reached, a
standardised further inflation with 13 atm and possibly
16 atm including additional IVUS control, followed. Post-
procedural an oral antiplatelet therapy with clopidogrel
75 mg/day for at least 4 weeks and aspirin 100 mg/day as
standard medication was obligatory.
Intravascular ultrasound imaging was performed after
administering 0.2 mg of intracoronary nitroglycerin using
a 30 MHz transducer within a 3.2 Fr imaging sheath (SCI-
MED/BSC, Maple Grove, Minnesota) and automatic
transducer pullback of 0.5 mm/s. The distal and proximal
reference segment was within 3 – 5 mm of the lesion or
stent without a relevant stenosis (<20%). Quantitative
Coronary Analysis (QCA, Pie Medical Imaging) was done
for proximal and distal reference diameter (RD), minimal
lumen diameter (MLD), diameter of stenosis and acute
lumen gain.
The primary endpoint was balloon deployment pressure
once IVUS criteria were reached. IVUS target criteria were
similar to preceding studies[5], with a minimal lumen
area (MLA) after stenting > 90% (for reference lumen area
(RLA) ≤ 9.0 mm2), > 80% (for RLA > 9.0 mm2), a MLA >
90% of proximal RLA at the proximal end of the stent and
a complete adherence to vessel wall. A secondary end-
point was angiographic visibility as generated by minimal
lumen diameter in QCA and IVUS-analysis, respectively.
Statistical analysis was performed with SPSS, version 12.0
(SPSS Inc., 2003). Continuous variables are expressed as
mean ± SD.
Results
Clinical data were comparable for both groups, except for
the number of smokers (Vision® n = 7 / Zeta® n = 3), and
Table 1: Baseline Lesion Characteristics (QCA).
ML Vision (n = 10) ML Zeta (n = 10)
Preprocedure reference vessel diameter (mm) 3.04 ± 0.34 2.99 ± 0.47
Preprocedure MLD (mm) 0.77 ± 0.32 0.63 ± 0.32
Preprocedure diameter stenosis (%) 73.50 ± 10.30 79.60 ± 8.80
Target vessel
Left anterior descending 20% 50%
Circumflex 20% 20%
Right coronary artery 60% 30%
Postprocedure MLD (mm) 3.34 ± 0.34 3.31 ± 0.48
Postprocedure diameter stenosis (%) 6.00 ± 1.80 5.10 ± 3.80Current Controlled Trials in Cardiovascular Medicine 2005, 6:17 http://cvm.controlled-trials.com/content/6/1/17
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were comparable to prior stent studies. Twenty five stents
(13 ML Vision®, 12 ML Zeta®) were implanted with a
100% procedural success. An intraprocedural dissection
in 3 patients required implantation of additional stents.
In case of stent overlap, the same stent type was used.
The angiographic mean reference vessel diameter was 3.02
± 0.40 mm (ML Vision® 3.04 ± 0.34 mm / ML Zeta® 2.99 ±
0.47 mm). Mean minimum lumen diameter was 0.70 ±
0.32 mm, which corresponds to a mean diameter stenosis
of 76.5 ± 9.8% (Table 1).
Pre-dilatation was necessary in one case, in which a 1.5 ×
20 mm balloon was used and dilatation pressure was 8
atm.
Mean balloon deployment pressure when IVUS criteria
were reached was 13.90 ± 2.03 atm for Multi-Link Vision®
and 11.50 ± 2.12 atm for Multi-Link Zeta® (Figure 1).
A mean post-procedural QCA-MLD of 3.32 ± 0.41 mm
and a mean MLD of 3.07 ± 0.41 mm by intravascular
ultrasound generated a mean Visibility-Index of 1.08. For
Multi-Link Vision® (3.34 ± 0.34 mm [QCA] vs. 2.95 ± 0.17
mm [IVUS]), mean Visibility-Index was 1.13. The mean
Visibility-Index for Multi-Link Zeta® (3.31 ± 0.48 mm
[QCA] vs. 3.19 ± 0.55 mm [IVUS]) was 1.04 (Table 2).
Conclusion
Different material properties of alloys used in a specific
stent design represent a key consideration in clinical prac-
Ballon pressure by IVUS-criteria Figure 1
Ballon pressure by IVUS-criteria: balloon deployment pressure when IVUS criteria were reached for Multi-Link Vision® 
and Multi-Link Zeta® (n = number of lesions).
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tice that should be taken into account, particularly with
regard to balloon deployment pressure. Furthermore, the
achieved post-procedure lumen diameter as measured by
QCA is more easily overestimated for the cobalt chro-
mium stent than for the stainless steel stent due to mate-
rial properties.
Based on these results, further investigation of material-
specific changes in stent unfolding is necessary to guide
and optimize the clinical implantation practice.
Limitations
The number of twenty de novo native coronary stenoses is
small, but relevant preliminary differences were found
that should be further explored in future investigations.
Three standardised balloon deployment pressures (10,
13, 16 atm) were chosen because every change between
balloon and IVUS-catheter increases the risk of vascular
damage. Thus, a continuous, incremental escalation of
balloon deployment pressure is not practical in vivo.
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Table 2: Visibility-Index: generated from QCA- and IVUS-data.
All ML Vision ML Zeta
Postprocedure MLD QCA (mm) 3.32 ± 0.41 3.34 ± 0.34 3.31 ± 0.48
Postprocedure MLD IVUS (mm) 3.07 ± 0.41 2.95 ± 0.17 3.19 ± 0.55
Visibility [QCA/IVUS] 1.08 1.13 1.04